Document is current
Any future updates will be listed below
-
Authors
Rathje, Kristin
Gagelmann, Nico https://orcid.org/0000-0002-0891-1744
Salit, Rachel B. https://orcid.org/0000-0002-4060-9393
Schroeder, Thomas
Gurnari, Carmelo https://orcid.org/0000-0001-6829-5544
Pagliuca, Simona
Panagiota, Victoria
Rautenberg, Christina
Cassinat, Bruno https://orcid.org/0000-0002-6514-3905
Thol, Felicitas
Robin, Marie
Oechsler, Sofia
Heuser, Michael https://orcid.org/0000-0001-5318-9044
Rubio, Marie-Thérèse
Maciejewski, Jaroslaw P. https://orcid.org/0000-0002-6837-4346
Reinhardt, Hans Christian
Scott, Bart L.
Kröger, Nicolaus https://orcid.org/0000-0002-2961-4183
- License Information
-
More Information
Article History
Received: 14 February 2024
Revised: 3 April 2024
Accepted: 12 April 2024
First Online: 21 May 2024
Competing interests
: KR and NG received a travel grant from Neovii. KR and NK received honoraria from Neovii. HCR received consulting and lecture fees from AbbVie, AstraZeneca, Roche, Janssen-Cilag, Novartis, Vertex and Merck. HCR received research funding from Gilead and AstraZeneca. HCR is a co-founder of CDL Therapeutics GmbH. The remaining authors declare no conflict of interest.
